Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

Core Insights - Myomo, Inc. reported a quarterly loss of $0.11 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.03 per share a year ago [1] - The company achieved revenues of $9.65 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 6.42%, and up from $7.52 million year-over-year [2] - Myomo shares have declined approximately 71.6% year-to-date, contrasting with the S&P 500's gain of 8.6% [3] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [1] - Myomo has topped consensus revenue estimates four times in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $12.83 million, and -$0.16 on revenues of $50.34 million for the current fiscal year [7] Market Outlook - The Zacks Rank for Myomo is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] - The outlook for the Medical - Products industry, to which Myomo belongs, is currently in the bottom 38% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The correlation between near-term stock movements and earnings estimate revisions is emphasized, indicating that investors should monitor these trends closely [5]